Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Operating Income (2022 - 2026)

TriSalus Life Sciences has reported Operating Income over the past 5 years, most recently at -$8.4 million for Q1 2026.

  • For Q1 2026, Operating Income fell 14.76% year-over-year to -$8.4 million; the TTM value through Mar 2026 reached -$28.0 million, up 11.92%, while the annual FY2025 figure was -$26.9 million, 25.49% up from the prior year.
  • Operating Income for Q1 2026 was -$8.4 million at TriSalus Life Sciences, down from -$3.3 million in the prior quarter.
  • Over five years, Operating Income peaked at -$288273.0 in Q2 2022 and troughed at -$18.6 million in Q3 2023.
  • A 5-year average of -$8.6 million and a median of -$8.4 million in 2026 define the central range for Operating Income.
  • Biggest five-year swings in Operating Income: plummeted 3866.38% in 2023 and later soared 56.85% in 2025.
  • Year by year, Operating Income stood at -$11.8 million in 2022, then decreased by 21.03% to -$14.2 million in 2023, then skyrocketed by 46.8% to -$7.6 million in 2024, then soared by 56.85% to -$3.3 million in 2025, then crashed by 157.14% to -$8.4 million in 2026.
  • Business Quant data shows Operating Income for TLSI at -$8.4 million in Q1 2026, -$3.3 million in Q4 2025, and -$9.0 million in Q3 2025.